News & Events
MimiVax to present results of SurVaxM immunotherapy in glioblastoma at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting
Clinical-stage biotechnology company also sharing its accomplishments to date and future plans at the 2019 Biotechnology Innovation Organization (BIO) International…
Roswell Park Research on Survivin Opens Up New Avenues for Cancer Immunotherapy
Molecule can exist on tumor surface, suggesting new opportunities for CAR T and antibody-based therapies BUFFALO, N.Y. — New research…
MimiVax awarded Orphan Drug Designation by US FDA for SurVaxM to treat glioblastoma patients
Novel immunotherapy, SurVaxM, being developed as treatment for glioblastoma BUFFALO, N.Y. — The U.S. Food and Drug Administration has awarded…
Clinical Trial Will Explore First-Time Use of SurVaxM Vaccine in Combination with REVLIMID® to Treat Rare Blood Cancer
Immunotherapy Developed at Roswell Park Being Tested as Treatment for Multiple Myeloma BUFFALO, N.Y. — An immune-based therapy developed at…
Promising Vaccine Therapy for Glioblastoma Brain Cancers Moves on to Larger, Multisite Study
Phase II clinical trial will assess efficacy of Roswell Park-developed immunotherapy in newly diagnosed patients BUFFALO, N.Y. — An innovative…
SurVaxM Phase I Completed
Phase I clinical trial results of SurVaxM presented at AACR Annual Meeting 2015 in Philadelphia BUFFALO, N.Y. — A first-of-its…